• Home
  • News
  • Portfolio News
  • Aircuity CEO Delivers Remarks on the Convergence of Supply and Demand Side Management at CERAWeek

Aircuity CEO Delivers Remarks on the Convergence of Supply and Demand Side Management at CERAWeek

14Mar

Aircuity CEO Delivers Remarks on the Convergence of Supply and Demand Side Management at CERAWeek

Portfolio News

Aircuity, the creator of measurably better environments, announced that CEO, Dan Diehl, spoke during CERAWeek 2018 on the evolving landscape of the built environment. CERAWeek is the world’s premier energy event with comprehensive insight into the global and regional energy future. Read more >>

Share this post

Related Posts

12Mar

Quthero Secures $500,000 Investment Boost from the Ontario Centre of Innovation

Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, proudly announces the successful acquisition of $500,000 in... read more
19Jan

RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial

RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the... read more
22Oct

HVAC Upgrades Aim to Reduce School Energy Use, COVID Spread

Though K-12 schools have been replacing outdated HVAC systems in recent years with air quality somewhat in mind, much of... read more
18Jul

Young Blind Girl Miraculously Gains Sight at LEGOLAND in Goshen

... The fun day at LEGOLAND was supposed to be the beginning of a new chapter for the family, but little did Arianna know that... read more
04Sep

Board adds $1M to help get more Utah students connected to internet

The board also approved setting aside $452,000 from the Utah K-12 CARES set aside funds to obtain a K-12 license... read more
01Mar

Xylyx Bio launches new website to showcase growing portfolio of regenerative biotechnologies

Xylyx Bio, a New York-based regenerative medicine company leading the development of advanced biomaterials and biosystems, is proud to announce... read more
07Mar

First Patient Dosed in Neuraly’s NLY01 Trial Testing Safety, Efficacy

The first patient has been dosed in a Phase 2 study testing NLY01, an investigational compound with a new mechanism... read more
14Jun

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to... read more
01Jun

Elizabeth Banks Tries Luxury Wine in a Can | Archer Roose

Meet the uninvited guest, Elizabeth Banks… She just sort of showed up one day. And before we knew it, she... read more
01Apr

Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it received regulatory approval in the Netherlands... read more